Nov 26, 2018 4:35pm EST IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
Nov 20, 2018 7:05am EST IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer
Nov 06, 2018 7:05am EST Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors
Nov 02, 2018 7:05am EDT IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details
Oct 23, 2018 7:05am EDT IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018
Sep 18, 2018 7:05am EDT IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL
Sep 11, 2018 7:05am EDT IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
